PHARMACEUTICAL FORMULATION FOR REDUCING FREQUENCY OF URINATION AND METHOD OF USE THEREOF
Methods and compositions for reducing frequency of urination are disclosed. The methods comprise administering to a subject having a condition that resulting in undesired frequency of urination an effective amount of a pharmaceutical composition comprising one or more prostaglandin pathway inhibitors. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 01. Juni Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Unbestimmt |
|---|
| Beteiligte Personen: |
DILL DAVID A [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
615 |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2014, Last update posted on www.epo.org: 2021-06-01, Last updated: 2021-06-21 |
|---|
| Patentnummer: |
EP3151834 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA005577071 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA005577071 | ||
| 003 | DE-627 | ||
| 005 | 20230503194017.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210531s2021 xx |||||o 00| ||und c | ||
| 035 | |a (DE-627)EPA005577071 | ||
| 035 | |a (EPA)EP3151834 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a und | ||
| 100 | 0 | |a DILL DAVID A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PHARMACEUTICAL FORMULATION FOR REDUCING FREQUENCY OF URINATION AND METHOD OF USE THEREOF |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2014, Last update posted on www.epo.org: 2021-06-01, Last updated: 2021-06-21 | ||
| 520 | |a Methods and compositions for reducing frequency of urination are disclosed. The methods comprise administering to a subject having a condition that resulting in undesired frequency of urination an effective amount of a pharmaceutical composition comprising one or more prostaglandin pathway inhibitors. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a RAUSCHER FRANK J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 01. Juni |
| 773 | 1 | 8 | |g year:2021 |g day:01 |g month:06 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/searchResults?DB=EPODOC&locale=en_EP&query=EP3151834A4 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2021 |b 01 |c 06 |
| 951 | |a AR | ||
| 952 | |j 2021 |b 01 |c 06 | ||